免疫分型
不确定意义的单克隆抗体病
多发性骨髓瘤
骨髓
医学
流式细胞术
单克隆
危险系数
病理
单克隆抗体
内科学
肿瘤科
免疫学
抗体
置信区间
作者
Ernesto Pérez‐Persona,Gema Mateo,Ramoń García‐Sanz,María‐Victoria Mateos,Natalia de las Heras,Alfonso García de Coca,José Hernández,Josefina Galende,Guillermo Martín–Núñez,Abelardo Bárez,José M. Alonso,Alejandro Martı́n,C. López‐Berges,Alberto Órfão,Jesús F. San Miguel,María‐Belén Vidriales
标识
DOI:10.1111/j.1365-2141.2009.07929.x
摘要
The present study explored the impact of two novel criteria; having >95% abnormal plasma cells by flow cytometry at diagnosis and the evolving subtype of the disease, as predictors of progression in 61 smouldering multiple myeloma (SMM) and 311 monoclonal gammopathy of unknown significance (MGUS) patients. Although both criteria were of prognostic value, the risk of progression was better identified by immunophenotyping [Hazard Ratio (HR) 6.2 and 17.2 for SMM and MGUS, respectively] than evolving subtype, which had independent prognostic value only in MGUS (HR 3.6). Immunophenotyping discriminated the different risk of progression within the evolving and non-evolving subgroups of SMM (P = 0.01) and MGUS (P < 0.001).
科研通智能强力驱动
Strongly Powered by AbleSci AI